Defining disease-modifying therapies for PD--a road map for moving forward

Area of Science:

• Neuroscience
• Clinical Trials
• Pharmacology

Background:

• Parkinson's disease (PD) management lacks disease-modifying therapies, representing a significant unmet clinical need.
• Current clinical trials face challenges in distinguishing true disease modification from symptomatic effects.
• No therapy has been approved for disease modification in PD despite preclinical promise.

Purpose of the Study:

• To propose a roadmap for defining and evaluating disease-modifying drugs for Parkinson's disease.
• To address the limitations of current clinical trial designs in assessing long-term therapeutic effects on disease progression.

Main Methods:

• Critically evaluate the delayed start study design for its ability to isolate non-symptomatic treatment benefits.
• Analyze the long-term simple study design for its capacity to measure cumulative disability reduction.
• Propose a combined approach using both trial designs to comprehensively assess disease modification.

Main Results:

• Delayed start studies can identify benefits beyond early symptomatic effects.
• Long-term simple studies effectively measure cumulative disease impact.
• Neither design alone fully captures the necessary data for definitive disease modification assessment.

Conclusions:

• A combination of delayed start and long-term simple study designs is essential for validating Parkinson's disease-modifying therapies.
• This integrated approach provides a robust framework for determining true disease modification and its long-term impact on cumulative disability.